|
T37207L |
Cdk5 Substrate acetate
|
|
CDK
|
|
Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine kinase that is predominantly active in neuronal tissues. With p25 or p35, Cdk5 phosphorylates a range of proteins, including histone H1 and tau. Cdk5 Substrate aceta... |
|
T37207 |
Cdk5 Substrate
|
Cdk5 Substrate |
|
|
Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine kinase that is predominantly active in neuronal tissues. With p25 or p35, Cdk5 phosphorylates a range of proteins, including histone H1 and tau. Cdk5 substrate is a ... |
|
T40263 |
CDK5-IN-1
|
CDK5-IN-1 |
|
|
CDK5-IN-1 is a highly potent inhibitor of CDK5, displaying an inhibitory activity of less than 10 nM. This potent compound is specifically employed in scientific investigations relating to kidney diseases. |
|
T36742 |
CDK5 inhibitor 20-223
|
CDK5 inhibitor 20-223 |
|
|
CDK5 inhibitor 20-223, a potent inhibitor of CDK2 and CDK5, demonstrates IC50 values of 6.0 nM and 8.8 nM, respectively. It serves as an effective agent against colorectal cancer (CRC)[1]. |
|
T35555 |
GSK-3/CDK5/CDK2-IN-1
|
GSK-3/CDK5/CDK2-IN-1 |
|
|
GSK-3/CDK5/CDK2-IN-1 is an imidazole derivative compound that inhibits cdk5, cdk2, and GSK-3.it has demonstrated applications in cancer research and the study of neurodegenerative diseases [1]. |
|
TP1602 |
[pThr3]-CDK5 Substrate
|
|
|
|
[pThr3]-CDK5 Substrate is an effective Phospho-Thr3CDK5 Substrate.[pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM[1]. |
|
TP1660 |
[pThr3]-CDK5 Substrate (TFA)
|
|
|
|
[pThr3]-CDK5 Substrate TFA is an effective Phospho-Thr3CDK5 Substrate. [pThr3]-CDK5 Substrate is phosphorylated by CDK5 with a Km value of 6 µM. |
|
T61362 |
CDK5-IN-3
|
|
|
|
CDK5-IN-3 (compound 11) is a highly potent and selective inhibitor of CDK5, demonstrating significant inhibition with IC50 values of 0.6 nM and 18 nM for CDK5/p25 and CDK2/CycA, respectively. This compound holds promise ... |
|
T63184 |
CDK5-IN-2
|
|
|
|
CDK5-IN-2 (compound 15) is a highly selective CDK5 inhibitor that acts on CDK5/p25 (IC50: 0.2 nM) and CDK2/CycA (IC50: 23 nM). |
|
T76031 |
[pThr3]-CDK5 Substrate TFA
|
|
|
|
[pThr3]-CDK5 Substrate TFA, a potent Phospho-Thr3CDK5 Substrate, originates from the histone H1 peptide sequence that binds to CDK5's active site. This substrate undergoes phosphorylation by CDK5, demonstrating a K_m val... |
|
T7426 |
ALSTERPAULLONE
|
|
Apoptosis
,
GSK-3
,
CDK
|
|
Alsterpaullone is a Cyclin-Dependent Kinase Inhibitor, Mediated Toxicity in HeLa Cells Through Apoptosis-Inducing Effec |
|
T7167 |
Purvalanol B
|
NG 95 |
CDK
,
Parasite
|
|
Purvalanol B (NG 95) is a CDK inhibitor that inhibits Cdk2/cyclin A, Cdk2/cyclin E, Cdk5/p35, and Cdk2/cyclin B (IC50s = 6, 9, 6, and 6 nM, respectively) |
|
T8230 |
PNU112455A hydrochloride
|
PNU 112455A |
CDK
|
|
PNU112455A hydrochloride is an ATP site competetive inhibitor of CDK2 and CDK5,binds to the ATP site of CDK2 and CDK5 with Kms of 3.6 and 3.2 μM, respectively. |
|
TQ0068 |
NVP-LCQ195
|
AT9311,LCQ-195 |
CDK
|
|
NVP-LCQ195 (LCQ-195) (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM). |
|
T2440 |
IC261
|
SU-5607 |
Apoptosis
,
Casein Kinase
,
CDK
|
|
IC261 (SU-5607) is a novel inhibitor of CK1, triggers the mitotic checkpoint control. The IC50 of IC261 for CK1 was 16 μM and for Cdk5 is 4.5 mM. |
|
T77341 |
GSK-3 inhibitor 4
|
|
GSK-3
,
CDK
|
|
GSK-3 inhibitor 4 is an orally active and brain-permeable triple inhibitor of GSK-3, CDK2 and CDK5 with inhibitory effects on GSK-3β, GSK-3α, CDK2 and CDK5, with IC50 values of 0.56 nM, 0.45 nM, 0.47 μM, 0.68 μM, respect... |
|
T2095 |
Seliciclib
|
Roscovitine,R-roscovitine,CYC202 |
CDK
|
|
Seliciclib (Roscovitine) is a potent inhibitor of Cdk2/cyclin E (IC50: 0.1 μM). It also inhibits Cdk7/cyclin H, Cdk5/p35, and Cdc2/cyclin B (IC50s: 0.49/0.16/0.65 μM). |
|
T5200 |
Indirubin-3'-monoxime
|
Indirubin-3'-oxime |
GSK-3
,
Lipoxygenase
,
CDK
|
|
Indirubin-3'-monoxime (Indirubin-3'-oxime) is a potent inhibitor of GSK3β (IC50: 22 nM) and also inhibits CDKs ( (IC50s: 100/180/250 nM for Cdk5/p35, Cdk1/cyclin B, Cdk2/cyclin E). |
|
T1912 |
Dinaciclib
|
SCH 727965,PS-095760 |
Apoptosis
,
CDK
|
|
Dinaciclib (SCH 727965) is a CDK inhibitor that selectively inhibits CDK1, CDK2, CDK5, and CDK9 (IC50 score = 3/1/1/4 nM). Dinaciclib has potential antitumor activity and inhibits the incorporation of thoracic glycan (dT... |
|
T2247 |
KenPaullone
|
9-Bromopaullone,NSC-664704 |
GSK-3
,
CDK
|
|
KenPaullone (9-Bromopaullone), a potent CDK1, CDK2 and CDK5 inhibitor, as new enhancer for iTreg cell differentiation. Kenpaullone promotes iTreg cell differentiation through increased and prolonged transcription of foxp... |
|
T1917 |
GSK 3 Inhibitor IX
|
BIO,GSK 3 IX,6-BIO,6-Bromoindirubin-3'-oxime,MLS 2052,6-bromoindirubin-3-oxime |
Apoptosis
,
GSK-3
,
Tyrosine Kinases
,
CDK
|
|
GSK 3 Inhibitor IX (6-BIO) is a selective reversible, ATP-competitive inhibitor of GSK-3α/β and CDK1-cyclinB complex. It inhibits (GSK-3α/β)/CDK1/CDK5 activity with IC50 values of 5 nM/320 nM/83 nM, respectively. |
|
T23389 |
SR1664
|
SR 1664 |
PPAR
|
|
SR1664 is a potent and selective PPARγ inhibitor with potential antidiabetic activity. SR1664 binds to PPARγ and potently inhibits Cdk5-mediated PPARγ phosphorylation (IC50 = 80 nM; Ki = 28.67 nM) without exhibiting PPAR... |
|
T36964 |
BML-259
|
CAY10554 |
CDK
|
|
BML-259 is an inhibitor of CDK5 and CDK2 with IC50s of 64 and 98 nM, respectively. BML-259 can be used in studies about the treatment of cancer and neurodegenerative diseases. |
|
T6358 |
1-Azakenpaullone
|
azakenpaullone |
GSK-3
|
|
1-Azakenpaullone (azakenpaullone) is a potent and selective GSK-3β inhibitor with IC50 of 18 nM, >100-fold selectivity over CDK1/cyclin B and CDK5/p25. |
|
T61439 |
DSS30
|
|
Beta Amyloid
,
BACE
,
CDK
|
|
DSS30 is a P25/CDK5 inhibitor.DSS30 acts by inhibiting the phosphorylation of amyloid precursor protein cleaving enzyme 1 (BACEl), which reduces the secretion of β-amyloid (Aβ).DSS30 can be used for the prevention and tr... |
|
T21588 |
Olomoucine
|
|
ERK
,
CDK
|
|
Olomoucine is an ATP competitive inhibitor of Cdk2/cyclin A, Cdc2/CyclinB, CDK2/CyclinE, CDK5/p35, and ERK1/p44 MAP kinase with IC50s of 7, 7, 7, 3 and 25 µM, respectively. Olomoucine regulates cell cycle and exhibits an... |
|
T6940 |
PHA-767491 hydrochloride
|
CAY10572,PHA-767491,PHA767491 HCl,CAY-10572 hydrochloride |
Apoptosis
,
GSK-3
,
CDK
|
|
PHA-767491 hydrochloride (CAY-10572 hydrochloride) is an effective ATP-competitive dual Cdc7/CDK9 inhibitor (IC50: 10/34 nM). It has ~20-fold selectivity against GSK3-β and CDK1/2, 50-fold selectivity against CDK5 and MK... |
|
T21720 |
GP-82996
|
Cdk4/6 Inhibitor IV,CINK4 |
CDK
|
|
GP-82996 (CINK4) is a pharmacological inhibitor specifically targeting CDK4/6, exhibiting IC50 values of 1.5 μM for CDK4/cyclin D1, 5.6 μM for CDK6/cyclin D1, and 25 μM for Cdk5/p35. It effectively induces apoptosis in U... |
|
T6787 |
BIO-acetoxime
|
BIA,GSK-3 Inhibitor X |
Apoptosis
,
GSK-3
,
HSV
|
|
BIO-acetoxime (GSK-3 Inhibitor X) is a potent dual GSK3α/β inhibitor with IC50 of 10 nM, >240-fold selectivity over CDK5/p25, CDK2/cyclin A and CDK1/cyclin B. |
|
T22260 |
Aminopurvalanol A
|
|
CDK
|
|
Aminopurvalanol A is a competitive, selective and cell-permeable inhibitor of cyclin-dependent kinase (CDK) that potently inhibits Cyclin A/cdk2, Cyclin B/cdk1, Cyclin E/cdk2, and P35/cdk5 with IC50 of 33 nM, 33 nM, 28 n... |
|
T2378 |
RGB-286638 free base
|
|
GSK-3
,
MEK
,
JAK
,
CDK
|
|
RGB-286638 free base is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively; less potent against cyclin H-CDK7 a... |
|
T10898 |
Samuraciclib hydrochloride
|
ICEC0942 hydrochloride,CT7001 hydrochloride |
Apoptosis
,
CDK
|
|
Samuraciclib hydrochloride (ICEC0942 hydrochloride) is a potent, selective, ATP competitive and oral active CDK7 inhibitor with IC50 of 41 nM. The selectivity of Samuraciclib hydrochloride is 45-, 15-, 230- and 30-fold h... |
|
T2506 |
AZD-5438
|
AZD5438 |
CDK
|
|
AZD-5438 is an effective inhibitor of CDK, for CDK1(IC50=16 nM), CDK2(IC50=6 nM), CDK9(IC50=20 nM). |
|
T2059 |
Purvalanol A
|
NG-60 |
Apoptosis
,
CDK
,
Autophagy
|
|
Purvalanol A (NG-60) is an effective and cell-permeable CDK inhibitor with IC50 of 70/4/35/850 nM for cdk2-cyclin A/B/E, and cdk4-cyclin D1, respectively. |
|
T14943 |
CGP60474
|
|
VEGFR
,
CDK
,
PKC
|
|
CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC. CGP60474 is also a highly potent anti-endotoxemic agent and inhibits cyclin-dependent kinase (CDK) potently. |
|
T11652 |
Indirubin-3'-monoxime-5-sulphonic acid
|
|
Others
|
|
Indirubin-3'-monoxime-5-sulphonic acid is a potent and selective inhibitor of GSK-3β, CDK5, and CDK1 with IC50s of 80nM,5 nM, and 7 nM, respectively. |
|
T71486 |
NS-0011
|
|
|
|
NS-0011 is an inhibitor of CDK5 translocation which increases CDK5 accumulation in the nucleus, suppressing both cancer cell proliferation and xenograft tumorigenesis. |
|
T10172 |
5-Iodo-indirubin-3'-monoxime
|
|
GSK-3
,
CDK
|
|
5-Iodo-indirubin-3'-monoxime is a potent GSK-3β, CDK5/P25 and CDK1/cyclin B inhibitor, competing with ATP for binding to the catalytic site of the kinase (IC50s: 9, 20 and 25 nM). |
|
T21377 |
Aloisine A
|
|
|
|
Aloisine A is a potent and selective CDK/GSK-3 inhibitor. IC50 data of Aloisine A: Cdk1/cyclin B (IC50: 150nM), Cdk2/cyclin A (IC50: 120nM), Cdk2/cyclin E (IC50: 400nM), Cdk5/p25 (IC50: 200nM), Cdk5/p35 (IC50: 160nM), GS... |
|
T22590 |
AT7519 TFA
|
AT7519 trifluoroacetate |
Others
|
|
AT7519 is a kinase inhibitor (IC50: 0.19, 0.044, 0.51, 0.067, 0.66 and 0.018 μM for CDK1/cyclinB, CDK2/CyclinA, CDK2/Cyclin E, CDk4/CyclinD1, CDK6/Cyclin D3, CDk5/p35). |
|
T24734 |
RP-106
|
RP 106 |
|
|
RP-106 is an ATP-competitive inhibitor of CDK5/p25, CDK1/cyclin B, and GSK-3. |
|
T25650 |
LDN-193665
|
LDN 193665,LDN193665 |
|
|
LDN-193665 is a potent inhibitor of tau kinase. It acts by targeting CDK5/p25 and GSK3β. |
|
T62694 |
(S)-GFB-12811
|
|
|
|
(S)-GFB-12811 (compound 596) is a selective and selective inhibitor of CDK5 (IC50<10 nM). (S)-GFB-12811 can be used in studies of cell cycle progression, neuronal development, and tumorigenesis. |
|
T11653 |
Indirubin-5-sulfonate
|
|
Others
|
|
Indirubin-5-sulfonate shows inhibitory activity against GSK-3β. Indirubin-5-sulfonate is a cyclin-dependent kinase (CDK) inhibitor, with IC50 values of 55 nM, 35 nM, 150 nM, 300 nM and 65 nM for CDK1/cyclin B, CDK2/cycli... |
|
T61890 |
(E/Z)-BIO-acetoxime
|
|
|
|
(E/Z) - BIO-acetoxime is effective and selective GSK-3 α/β Inhibitors. For GSK-3 α/β, CDK5/p25, CDK2/cyclin A and CDK1/cyclin B, IC50 are 10nM, 2.4 μM, 4.3 μ M, 63 μ M, respectively。 |
|
T39943 |
CDK7-IN-6
|
CDK7-IN-6 |
|
|
CDK7-IN-6 is a highly effective and specific inhibitor (IC50 ≤100 nM) of cyclin-dependent kinase 7 (CDK7). It showcases remarkable selectivity, with more than a 200-fold preference for CDK7 over CDK1, CDK2, and CDK5. Thi... |
|
T62554 |
PPARγ phosphorylation inhibitor 1
|
|
|
|
PPARγ phosphorylation inhibitor 1 (Compound 10) is a potent PPARγ binding agent (IC50: 24 nM) with antidiabetic effects. PPARγ phosphorylation inhibitor 1 exhibited inhibition of CDK5-mediated PPARγ Ser273 phosphorylatio... |
|
T62695 |
GFB-12811
|
|
|
|
GFB-12811 is a highly selective and orally active inhibitor of cyclin-dependent kinase 5 (CDK5), exhibiting an inhibitory concentration (IC50) of 2.3 nM. It demonstrates notable specificity, with minimal activity against... |
|
T73163 |
CDK7-IN-20
|
|
|
|
CDK7-IN-20 is a potent, selective, and irreversible inhibitor of Cyclin-Dependent Kinase 7 (CDK7) with an IC50 value of 4 nM, exhibiting over 206-fold selectivity against related kinases CDK1, CDK2, CDK3, CDK5, CDK6, CDK... |
|
T63437 |
CDK1-IN-5
|
|
|
|
CDK1-IN-5 (10h) is a selective CDK1 inhibitor that acts on CDK1 (IC50: 42.19 nM), CDK2 (IC50: 188.71 nM) and CDK5 (IC50: 354.15 nM). CDK1-IN-5 affects the cell cycle and inhibits cancer cell growth and can be used in can... |
